Clinical trial · Observational
Cardiotoxic Effects of Chemotherapy in Patients With Sarcomas: A Two and Three-dimensional Echocardiographic Speckle Tracking Imaging Study
Cardiotoxic Effects of Chemotherapy in Patients With Sarcomas: A Two and Three-Dimensional Echocardiographic Speckle Tracking Imaging Study
NCT06511388CI-TRIAL-00096492terminatedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Low accrual
Summary
Brief summary (as posted)
This study is being done to identify markers that will allow researchers to identify in advance patients with sarcomas who are at highest risk for developing heart failure related to chemotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Sarcoma | Sarcoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Non-Interventional Study | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Observational
- description
- Patients receive anthracycline once a day or split between 2-3 days per SOC. Patients undergo 2D-STE throughout the study and have their medical records reviewed on study.
- interventionNames
- Other: Non-Interventional Study
Primary outcomes (4)
- measure
- Changes in myocardial function - 2D-STE
- timeFrame
- Baseline, 3 months, 6 months, 1 year
- description
- Changes in myocardial function will be assessed using 2D-STE derived strain rate. Changes will be compared to baseline over time.
- measure
- Changes in myocardial function - 2D-STE vs 3D-STE
- timeFrame
- Baseline, 3 months, 6 months, 1 year
- description
- Differences between two-dimensional speckle tracking echocardiography (2D-STE) and three-dimensional speckle tracking echocardiography (3D-STE) derived strain will be compared at baseline and over time.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients followed at Mayo Clinic and treated for sarcoma with doxorubicin as first-line treatment Exclusion Criteria: * First-line treatment not including doxorubicin * Treatment performed outside of Mayo Clinic with different protocols * Age \< 18 years
References
Publications (0)
Data not yet available
No reference posted for this study.